MapLight Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MapLight Therapeutics, Inc. on August 13, 2026. The filing primarily announces a material definitive agreement regarding a private placement financing and provides preliminary financial data as of June 30, 2026.
Key Financial Metrics
- Financing Proceeds: The Company entered into a Securities Purchase Agreement to raise approximately $150.0 million in gross proceeds.
- Offering Structure: The transaction involves the sale of 9,197,887 shares of Common Stock and pre-funded warrants for 3,983,168 shares.
- Purchase Price: Common Stock was sold at $11.38 per share; Pre-Funded Warrants were sold at $11.3799 per share.
- Liquidity Position: As of June 30, 2026, cash, cash equivalents, and investments totaled $351.3 million.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
- Debt: The filing text does not provide specific debt figures.
Material Changes and Transaction Details
The primary material change is the execution of a private placement transaction with institutional investors. The Company engaged Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated as placement agents. A Registration Rights Agreement was also signed, requiring the Company to file a registration statement within 30 days of closing. Failure to meet filing or effectiveness deadlines may result in liquidated damages of 1.0% per 30-day period.
Guidance, Outlook, and Risks
The Company updated its corporate presentation for investor meetings on August 13, 2026, though specific forward-looking guidance numbers are not detailed in this filing text. The Pre-Funded Warrants include beneficial ownership limitations, capping ownership at 19.99% unless adjusted with 61 days' notice. The securities were sold in a private placement under Section 4(a)(2) of the Securities Act and are not registered for public resale until the registration statement becomes effective.
Investor Verification Checklist
- Verify the final closing date and net proceeds after deducting placement agent fees and offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the status of the registration statement filing required under the Registration Rights Agreement (Exhibit 10.2).
- Examine the Q2 2026 press release (Exhibit 99.1) for detailed operational results and cash burn rates not included in this summary.
- Assess the impact of the new share issuance on existing shareholder dilution.